Tumor immunotherapy: inching toward the finish line.

@article{Curiel2002TumorII,
  title={Tumor immunotherapy: inching toward the finish line.},
  author={Tyler Jay Curiel and David T. Curiel},
  journal={The Journal of clinical investigation},
  year={2002},
  volume={109 3},
  pages={311-2}
}
Despite significant advances in therapy for early-stage cancer, the prognosis for most advanced-stage tumors remains little changed over the past 50 years (1). A vast array of novel strategies has been introduced over this period, many of them building on a recent explosion of insights into tumor immunology. Early attempts at cancer immunotherapy focused on IL-2 or other T cell–activating cytokines that were intended to expand the number or potency of T cells specific for tumor-associated… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
7 Extracted Citations
6 Extracted References
Similar Papers

Similar Papers

Loading similar papers…